Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

← catalyst calendar

NCT02811861 · results posted

Sponsored by Eisai Inc. (industry) · 4523.T — their whole pipeline →. With Merck Sharp & Dohme LLC.

Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
1,069actual
Sites
183
Countries
Australia, Austria, Belgium +17

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2016-10-13actualWhen the study began enrolling
Primary completion2020-08-28actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2027-03-31estimatedThe whole study's end, after follow-up
First posted2016-06-23estimatedWhen this record first appeared on the registry
Results posted2021-09-24actualWhen the sponsor posted results to the registry
Record updated2026-02-23actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Renal Cell Carcinoma

Interventions

  • Drug: Lenvatinib
  • Drug: Everolimus
  • Drug: Pembrolizumab
  • Drug: Sunitinib

Primary outcome

what the primary-completion date above is the date OF
Progression-free Survival (PFS) by Independent Imaging Review (IIR)
measured From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to data cutoff date 28 Aug 2020 (up to approximately 46 months)

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2020-08-06 · 1.8 MB · Prot_000.pdf
Statistical Analysis Planposted 2020-08-14 · 756 KB · SAP_001.pdf

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · 4523.T's whole pipeline · Catalyst calendar · Every registered study · What changed